Epidermal growth factor and necrotizing enterocolitis

Area of Science:

• Neonatal Medicine
• Gastroenterology
• Biochemistry

Background:

• Necrotizing enterocolitis (NEC) is a significant cause of morbidity and mortality in extremely low-birth-weight (ELBW) infants.
• The incidence of NEC is increasing with advances in neonatal intensive care.
• Current management strategies for NEC are limited, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To evaluate the potential of epidermal growth factor (EGF) as a therapeutic agent to reduce the incidence of intestinal inflammation and NEC in ELBW infants.
• To explore the role of EGF, a component of breast milk, in protecting the neonatal gut.

Main Methods:

• Review of existing literature on NEC and EGF.
• Analysis of basic research and clinical studies investigating EGF supplementation in enteral feeds.
• Assessment of the safety and efficacy of EGF in preclinical and clinical settings.

Main Results:

• Epidermal growth factor is a biologically active substance found in breast milk.
• Supplementation of enteral feeds with EGF shows promise in reducing intestinal inflammation.
• EGF may offer a protective effect against the development of NEC.

Conclusions:

• Supplementing enteral nutrition with epidermal growth factor is a potentially safe and logical strategy to mitigate NEC in ELBW infants.
• Further basic research and clinical trials are necessary to establish EGF as an effective therapeutic option for neonatal NEC.
• EGF supplementation warrants continued investigation as a promising intervention for preventing and treating NEC.